Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345255 | 0.87 | GABRP (0.38) | BTKHSD17B10KDM4E | |
| SCHEMBL6351818 | 0.84 | BTK (0.37) | BTKHSD17B10KDM4EHPGDTP53 | |
| SCHEMBL6354095 | 0.81 | L3MBTL1 (0.40) | EGFRHSD17B10KDM4EHPGDMAPK1 | |
| SCHEMBL6342478 | 0.78 | AR (0.40) | EGFRHSD17B10KDM4EHPGDMAPK1 | |
| SCHEMBL6351289 | 0.75 | NPSR1 (0.40) | EGFRHSD17B10KDM4EHPGDCHEK1 | |
| SCHEMBL6353601 | 0.71 | KDM4E (0.39) | KDM4EHPGDTSHRALDH1A1RAB9A | |
| SCHEMBL6339835 | 0.71 | KDM4E (0.37) | HSD17B10KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL6341201 | 0.70 | MAPT (0.40) | HSD17B10KDM4EHPGDMAPK1ALDH1A1 | |
| SCHEMBL6344220 | 0.69 | MEN1 (0.40) | HSD17B10KDM4EHPGDMAPK1NPC1 | |
| SCHEMBL6349093 | 0.68 | RAB9A (0.39) | HSD17B10KDM4EHPGDMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | BTK 3041/4885EGFR 4851/4885HSD17B10 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.